13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001395064
Total reported value
$16.4M
$16.4M
11 檔
110.8%
During the Q2 2025 filing period, Takeda Pharmaceutical Co LTD (CIK: 0001395064) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $16.4M across 11 reported positions.
During Q2 2025, Takeda Pharmaceutical Co LTD's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Hillevax Inc | Stock-Other | 68.43% | -60.21% | EXIT | |
| 2 | OVID | Ovid Therapeutics Inc | Stock-Other | 12.71% | +45.31% | — | |
| 3 | ✓ | Xilio Therapeutics Inc | Stock-Other | 5.13% | +0.99% | — | |
| 4 | AMWL | American Well Corp-class A | Stock-Other | 3.53% | -0.86% | — | |
| 5 | EQ | Equillium Inc | Stock-Other | 2.94% | +11.54% | — | |
| 6 | STTK | Shattuck Labs Inc | Stock-Other | 2.09% | +4.51% | — | |
| 7 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 1.86% | +2.71% | -95.00% | |
| 8 | ✓ | Turnstone Biologics CORP | Stock-Other | 1.64% | -2.27% | EXIT | |
| 9 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.02% | -0.79% | EXIT | |
| 10 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.53% | -0.96% | — | |
| 11 | LAB | Standard Biotools Inc | Stock-Other | 0.10% | +0.02% | — |
According to official SEC Form 13F filings, Takeda Pharmaceutical Co LTD reported a total U.S. public equity portfolio value of $16.4M across 11 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HILLEVAX INC, OVID, XILIO THERAPEUTICS INC) accounted for 110.8% of total reported equity market value during Q2 2025.
During Q2 2025, Takeda Pharmaceutical Co LTD's top holdings by market value included HILLEVAX INC (68.4%)、OVID (12.7%)、XILIO THERAPEUTICS INC (5.1%). The largest single position, HILLEVAX INC, represented 68.4% of total portfolio value.
In Q2 2025, Takeda Pharmaceutical Co LTD made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.